Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NCCAM Awards Funds For Ginkgo Biloba Trial, Five Research Centers

This article was originally published in The Tan Sheet

Executive Summary

The National Center for Complementary & Alternative Medicine is sponsoring a multicenter study to test the safety, efficacy and tolerability of ginkgo biloba for the prevention of dementia in the elderly, the center announced Sept. 30.

You may also be interested in...



Ginkgo biloba

Recruitment underway for four-year Oregon Health Sciences University study examining standardized ginkgo biloba extract's effects in preventing or delaying cognitive decline in people ages 85 and older. Randomized, double-blind trial is enrolling 200 cognitively healthy subjects who will be followed for mild cognitive impairment, a precursor to dementia. Subjects will be randomized to either placebo or 240 mg ginkgo extract per day. Placebo subjects will be placed on ginkgo 24 months after entry. Changes in MRI-determined volume will be assessed at baseline, 24 and 42 months. Principal investigator is Jeffrey Kaye, MD, director of OHSU's Oregon Aging & Alzheimer's Disease Center. OHSU received $7.8 mil. from NCCAM for neurological disorders research in 1999 (1"The Tan Sheet" Oct. 4, 1999, p. 4)

Ginkgo biloba

Recruitment underway for four-year Oregon Health Sciences University study examining standardized ginkgo biloba extract's effects in preventing or delaying cognitive decline in people ages 85 and older. Randomized, double-blind trial is enrolling 200 cognitively healthy subjects who will be followed for mild cognitive impairment, a precursor to dementia. Subjects will be randomized to either placebo or 240 mg ginkgo extract per day. Placebo subjects will be placed on ginkgo 24 months after entry. Changes in MRI-determined volume will be assessed at baseline, 24 and 42 months. Principal investigator is Jeffrey Kaye, MD, director of OHSU's Oregon Aging & Alzheimer's Disease Center. OHSU received $7.8 mil. from NCCAM for neurological disorders research in 1999 (1"The Tan Sheet" Oct. 4, 1999, p. 4)

Ginkgo biloba

Recruitment underway for four-year Oregon Health Sciences University study examining standardized ginkgo biloba extract's effects in preventing or delaying cognitive decline in people ages 85 and older. Randomized, double-blind trial is enrolling 200 cognitively healthy subjects who will be followed for mild cognitive impairment, a precursor to dementia. Subjects will be randomized to either placebo or 240 mg ginkgo extract per day. Placebo subjects will be placed on ginkgo 24 months after entry. Changes in MRI-determined volume will be assessed at baseline, 24 and 42 months. Principal investigator is Jeffrey Kaye, MD, director of OHSU's Oregon Aging & Alzheimer's Disease Center. OHSU received $7.8 mil. from NCCAM for neurological disorders research in 1999 (1"The Tan Sheet" Oct. 4, 1999, p. 4)

Related Content

Topics

UsernamePublicRestriction

Register

PS090388

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel